Economic implications of nesiritide versus dobutamine in the treatment of patients with acutely decompensated congestive heart failure

Gregory De Lissovoy, David M. Stier, Gabrielle Ciesla, Mark Munger, Andrew J. Burger

Research output: Contribution to journalArticlepeer-review

Abstract

Pooled data from trials comparing nesiritide with dobutamine for treatment of acute decompensated congestive heart failure were combined with national hospital cost data in an economic model. Results indicate that the acquisition cost of nesiritide is fully offset by decreased hospital costs.

Original languageEnglish (US)
Pages (from-to)631-633
Number of pages3
JournalThe American Journal of Cardiology
Volume92
Issue number5
DOIs
StatePublished - Aug 22 2003
Externally publishedYes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Economic implications of nesiritide versus dobutamine in the treatment of patients with acutely decompensated congestive heart failure'. Together they form a unique fingerprint.

Cite this